These findings were recently recapitulated by our group in cellular and orthotopic models of GBM, where six timepoints for TMZ dosing were assessed and dosing with TMZ at the daily peak of circadian clock gene BMAL1 expression was associated with significantly increased tumor cell death [11, 15]. The gene discussed is BMAL1; the disease is glioblastoma.